Abstract
Background
In the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease. Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance.
Discussion
One also hopes to derive improved prognostic factors from the clarification of the molecular pathogenesis. Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors. Despite a multitude of suggested molecular candidate markers none of these changes has yet been able enter the everyday life of the clinic. However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma.
Conclusion
Considering also our own findings, this review presents the latest developments in the scientific discussion of the tumor suppressor/oncogenes p53, k-ras, and DCC, biochemical determinants of the 5-fluorouracil metabolism, and defects of the DNA repair system.
Similar content being viewed by others
References
Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981–1990. Springer, Berlin Heidelberg New York
Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics. CA Cancer J Clin 47:5–27
Dukes CE, Bussey HJR (1958) The spread of rectal cancer and its effect on prognosis. Br J Cancer 12:309–320
Fielding LP (1986) Clinical-pathologic staging of large bowel cancer. Lancet 45:8–30
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection for stage III colon carcinoma: a final report. Ann Intern Med 122:321–326
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767
Fearon ER (1995) Molecular genetics of colorectal cancer. Ann N Y Acad Sci 768:101–110
Jen J, Kim H, Piantadosi S, Liu ZF, Liu ZF, Levitt RC, Sistonen P, et al (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213–221
Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351:453–456
Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318–1327
Chang F, Syrjanen S, Syrjanen K (1995) Implications of the p53-tumor-suppressor gene in clinical oncology. J Clin Oncol 4:1009–1022
Pereira H, Silva S, Juliao R, Garcia P, Perpetua F, et al (1997) Prognostic markers for colorectal cancer: expression of p53 and bcl2. World J Surg 21:210–213
Smith DR, Ji CY, Goh HS (1996) Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74:216–223
Soong R, Grieu F, Robbins P, et al (1997) p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405–1411
Elsaleh H, Powell B, McCaul K, et al (2001) P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7:1343–1349
Esteller M, González S, Risques RA, et al (2001) k-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19:299–304
Yang Y, Forslund A, Remotti, et al (2001) P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 91:727–736
Gervaz P, Bouzourene H, Cerottini J-P, et al (2001) Dukes B colorectal cancer. Distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 44:364–373
Diez M, Medrano M, Muguerza JM, et al (2000) Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. Anticancer Res 20:3907–3912
Gallego MG, Acenero MJ, Ortega S, et al (2000) Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 43:971–975
Bouzourene H, Gervaz P, Cerottini JP, et al (2000) P53 and k-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36:1008–1015
Nehls O, Klump B, Holzmann K, et al (1999) Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 85:2541–2548
Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, et al (1999) Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17:593–599
Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al (1999) Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17:1364–1374
Tollenaar RAEM, van Krieken JHJM, van Slooten HJ, Bruinvels DJ, Nelemans KMJ, van den Broek LJ, et al (1998) Immunohistochemical detection of p53 and BCL-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer 77:1842–1847
Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, et al (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58:1149–1158
Ilyas M, Hao X-P, Wilkinson K, et al (1998) Loss of bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 43:383–387
Wiggenraad R, Tamminga R, Blok P, et al (1998) The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 41:29–35
Caldes T, Iniesta P, de Juan C, et al (1998) Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer. Oncology 55:249–257
Starzynska T, Bromley M, Marlicz K, Roberts SA, Ucinski M, Stern PL (1997) Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma. Eur J Gastroenterol Hepat 9:183–186
Maeda K, Chung Y-S, Kang S-M, et al (1997) Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74:310–315
Poller DN, Baxter KJ, Shepherd NA (1997) P53 and RB1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 75:87–93
Bhatavdekar JM, Patel DD, Ghosh N, et al (1997) Coexpression of bcl-2, c-myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40:785–790
Baretton GB, Diebold J, Christoforis G, et al (1996) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77:255–264
Flamini G, Curigliano G, Ratto C, et al (1996) Prognostic significance of cytoplasmatic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer 32A:802–806
Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, et al (1996) P53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14:2696–2701
Leahy DT, Salman R, Mulcahy H, et al (1996) Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 180:364–370
Mulder JWR, Baas IO, Polak MM, Goodman SN, Offerhaus GJA (1995) Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 71:1257–1262
Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, et al (1995) Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:647–652
Diez M, Enriquez JM, Camunas J, et al (1995) Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Eur J Surg Oncol 21:635–639
Grewal H, Guillem JG, Klimstra DS, et al (1995) P53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis Colon Rectum 38:1176–1181
Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M (1994) Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 70:293–296
Bosari S, Viale G, Bossi P, et al (1994) Cytoplasmatic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86:681–687
Morrin M, Kelly M, Barrett N, Delaney P (1994) Mutations of ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 35:1627–1631
Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT (1994) Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 37:527–534
Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, et al (1994) P53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12:2043–2050
Tanaka M, Omura K, Watanabe Y, Oda Y, Nakanishi I (1994) Prognostic factors of colorectal cancer: k-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 57:57–64
Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y, Miyazaki I (1993) p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68:399–402
Bell S, Scott N, Cross D, Sagar P, Lewis FA, Blair E, et al (1993) Prognostic value of p53 overexpression and c-ki-ras gene mutations in colorectal cancer. Gastroenterology 104:57–64
Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P (1991) P53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63:317–319
Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, et al (1992) Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 66:758–764
Rosty C, Chazal M, Etienne M-C, et al (2001) Determination of microsatellite instability, p53 and k-ras mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer 95:162–167
Bleeker WA, Hayes VM, Karrenbeld A, et al (2001) Prognostic significance of k-ras and p53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum 44:358–363
Soong R, Powell B, Elsaleh H, et al (2000) Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36:2053–2060
Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA, et al (2000) P53 tumor supressor gene mutations predict decreased survival with sporadic colorectal carcinoma. Cancer 88:1814–1819
Liang JT, Cheng YM, Chang KJ, Chien CT, Hsu HC (1999) Reappraisal of k-ras and p53 gene mutations in the recurrence of Dukes B2 rectal cancer after curative resection. Hepatogastroenterology 46:830–837
Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, et al (1999) P53 and k-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17:1375–1381
Hardingham JE, Butler WJ, Roder D, Dobrovic A, Dymock RB, Sage RE, et al (1998) Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 42:669–672
Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al (1994) Association of p53 mutations with short term survival in colorectal cancer. Gastroenterology 106:42–48
Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12
Dix B, Robbins P, Carello A, House A, Iacopetta B (1994) Comparison of p53 gene mutation and protein overexpression in colorectal carcinoma. Br J Cancer 70:585–590
Wynford-Thomas D (1992) P53 in tumor pathology: can we trust immunocytochemistry? J Pathol 166:329
Barbacid M (1987) Ras genes. Annu Rev Biochem 56:779–827
Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB (1996) k-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 16:3839–3844
Font A, Abad A, Monzo M, Sanchez JJ, Guillot M, Manzano JL, et al (2001) Prognostic value of k-ras mutations and allelic imbalance of chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 44:549–557
Samowitz WS, Curtin K, Schaffer D, et al (2000) Relationship of Ki-ras mutations in colon cancer to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9:1193–1197
Kressner U, Bjorheim J, Westring S (1998) ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34:518–521
Andreyev HJNA, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90:675–684
Elnatan J, Goh HS, Smith DR (1996) C-ki-ras activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 32A:491–497
Kastrinakis WV, Ramchurren N, Maggard M, Steele G, Summerhayes IC (1995) k-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 130:9–14
Finkelstein SD, Sayegh R, Bakker A, Swalsky P (1993) Determination of tumor aggressiveness in colorectal cancer by k-ras-2 analysis. Arch Surg 128:526–532
Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M (1987) Detection of high incidence of k-ras oncogenes during human colon tumorigenesis. Nature 327:298–303
Capella G, Cronauer-Mitra S, Peinado M, Perucho M (1991) Frequency and spectrum of mutations at codon 12 and 13 of the c-k-ras gene in human tumors. Environ Health Perspect 93:125–131
Fearon E (1993) k-ras gene mutation as a pathogenic and diagnostic marker in human cancer. J Natl Cancer Inst 85:1978–1981
Fearon ER, Cho KR, Nigro JM, et al (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49–56
Cho KR, Fearon ER (1995) DCC: linking tumor suppressor genes and altered cell surface interactions in cancer? Eur J Cancer 31A:1055–1060
Itoh F, Hinoda Y, Ohe M, et al (1993) Decreased expression of DCC mRNA in human colorectal cancers. Int J Cancer 53:260–263
Lino H, Fukayama M, Maeda Y, et al (1994) Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 73:1324–1331
Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK (1995) The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene 10:1581–1586
Jernvall P, Mäkinen MJ, Karttunen TJ, Mäkelä J, Vihko P (1999) Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 79:903–908
Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR (1998) Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 114:1188–1195
Martinez-Lopez E, Abad A, Font A, et al (1998) Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 114:1180–1187
Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16:427–433
Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196–1206
Fazeli A, Dickinson SL, Hermiston ML, et al (1997) Phenotype of mice lacking functional deleted in colorectal cancer (DCC) gene. Nature 386:796–804
Gotley DC, Reeder JA, Fawcett J, et al (1995) The deleted in colorectal cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene 13:787–795
Hahn SA, Schutte M, Shamshul Hoque ATMS, et al (1996) DPC4: a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353
Eppert K, Scherer SW, Ozcelik H, et al (1996) MADR2 maps to 18q21 and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543–552
Sun XF, Rütten S, Zhang H, Nordenskjöld B (1999) Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol 17:1745
Halling KC, French AJ, McDonnell SK, et al (1999) Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 15:1295–1303
Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H, Furukawa K (1998) Reduced expression of deleted colorectal carcinoma protein in established colon cancers. Br J Cancer 77:466–471
Reymond MA, Dworak O, Remke S, Hohenberger W, Kirchner T, Köckeling F (1998) DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 41:755–760
Cohn KH, Ornstein DL, Wang F, et al (1997) The significance of allelic deletions and aneuploidy in colorectal carcinoma. Cancer 79:233–244
Shibata D, Reale MA, Lavin P, et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727–1735
Kato M, Ito Y, Kobayashi S, Isono K (1996) Detection of DCC and ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 77:1729–1735
Young J, Buttenshaw R, Butterworth L, et al (1994) Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers. Oncogene 9:1053–1056
Beverley SM, Ellenberger TE, Cordingly JS (1984) Primary structure the gene encoding the bifunctional dihydrofolate reduction-thymidylate synthase of Leishmania major. Proc Natl Acad Sci USA 83:2584–2589
Conrad AH, Ruddle FH (1972) Regulation of thymidylate synthase activity in cultured mammalian cells. J Cell Sci 10:471–486
Aschele C, Sobrero A, Faderan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-Fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855–1864
Copur S, Aiba K, Drake JC, et al (1995) Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49:1419
Leichman L, Lenz HJ, Leichman CG, et al (1995) Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31:1306–1310
YamachikaT, Nakanishi H, Inada KI, Tsukamoto T, Kato T, Fukushima M, et al (1998) A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82:70–77
Edler D, Kressner U, Ragnhammar, Johnston PG, Magnusson I, Glimelius B, et al (2000) Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 6:488–492
Cascinu S, Graziano F, Valentini, Catalano V, Giordani P Stacciolo MP, et al (2001) Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 12:239–244
Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A (2000) Thymidylate synthase protein expression in primary colorectal cancer compared with corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6:4797–4802
Cascinu S, Catalano V, Aschele C, Barni S, Debernadis D, Gallo L, et al (2000) Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann Oncol 11:1053–1056
Van Triest B, Pinedo HM, Blaauwgeers JLG, van Diest PJ, Schoenmakers PS, Voorn DA, et al (2000) Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063–1072
Edler D, Hallström M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2000) Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease free-survival and overall survival in rectal cancer. Clin Cancer Res 6:1378–1384
Aschele C, Debernardis D, Tunesi G, Bandelloni R, Cascinu S, Catalano V, et al (2000) Schedule-dependent correlation between the level of thymidylate synthase (TS) protein expression and clinical response to different 5-fluorouracil (5-FU) regimens in advanced colorectal cancer. Proc Am Soc Clin Oncol 19:251a
Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, et al (2000) Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560–567
Davies MM, Johnston PG, Kaur S, Allen-Mersh TG (1999) Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 5:325–328
Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, et al (1999) Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17:1760–1772
Cascinu S, Aschele C, Barni S, Debernadis D, Baldo C, Tunesi G, et al (1999) Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5:1996–1999
Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75:903–909
Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark M, Drake JC, et al (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640–2647
Lenz H-J, Hayashi K, Solonga D, Danenberg KD, Danenberg PV, Metzger R, et al (1998) P53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243–1250
Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223–3229
Kornmann M, Link KH, Lenz H-J, Pillasch J, Metzger R, Butzer U, et al (1997) Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 118:29–35
Gorlick R, Metzger R, Danenberg KD, Solonga D, Miles JS, Longo GSA, et al (1998) Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 16:1465–1469
Sanguedolce R, Vultaggio G, Sanguedolce F, Modica G, Li Volsi F, Diana G, et al (1998) The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18:1515–1520
Moghaddam A, Zang HAT, Fan TP, et al (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:988–1002
Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, et al (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110–1117
Metzger R, Danenberg K, Leichman CG, Solonga D, Schwartz EL, Wadler S, et al (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371–2376
Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, et al (2000) Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer 88:42–49
Naguib FNM, El Kouni AM, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic tissues. Cancer Res 45:5405
Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203–2206
Solonga D, Danenberg KD, Johnson M, et al (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327
Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260:812–816
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M, et al (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561
Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Järvinen H, et al (1993) Genetic mapping of a locus predisposing to human colorectal cancer. Science 260:810–812
Aaltonen LA, Peltomaki P, Mecklin JP, Järvinen H, Jass JR, Green JS, et al (1994) Replication errors in benign and malignant tumors from hereditary non-polyposis colorectal cancer patients. Cancer Res 54:1645–1648
Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkänen L, et al (1993) Genomic instability in colorectal cancer: relationship of clinicopathological variables and family history. Cancer Res 53:5849–5852
Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816–819
Kim H, Jen J, Vogelstein B, Hamilton SR (1994) Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145:148–156
Möslein G, Testet DJ, Lindor NM, Honchel R, Cunningham JM, French AJ (1996) Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 5:1245–1252
Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104:1535–1549
Guidoboni M, Gafà R, Viel A, Doglioni C, Russo A, Santini A, et al (2001) Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 159:297–304
Ward R, Meagher A, Tomlinson I, O'Connor T, Norrie M, Wu R, et al (2001) Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 48:821–829
Gafà R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, et al (2000) Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 89:2025–2037
Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL (2000) Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87:1197–1202
Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H (2000) Microsatellite instability as a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119:921–928
Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745–1750
Gonzalez-Garcia I, Moreno V, Navarro M, Marti-Rague J, Marcuello E, Benasco C, et al (2000) Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst 92:544–549
Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69–77
Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Chien CT, Wang SM (1999) Clinicopathological and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection. Hepatogastroenterology 46:883–890
Johannsdottir JT, Bergthorsson JT, Gretarsdottir S, Kristjansson AK, Ragnarsson G, Jonasson JG, et al (1999) Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 19:1821–1826
Jernvall P, Mäkinen MJ, Karttunen TJ, Mäkelä J, Vihkoo P (1999) Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer 35:197–201
Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Pahlman L, et al (1999) Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 81:190–193
Feeley KM, Fullard JF, Heneghan MA, Smith T, Maher M, Murphy RP, et al (1999) Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol 188:14–17
Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, et al (1996) Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12:2641–2649
Schmoll HJ, Büchele T, Grothey A, Dempke W (1999) Where do we stand with 5-FU? Semin Oncol 26:589–605
Author information
Authors and Affiliations
Corresponding author
Additional information
B. Klump and O. Nehls contributed equally to this manuscript
Rights and permissions
About this article
Cite this article
Klump, B., Nehls, O., Okech, T. et al. Molecular lesions in colorectal cancer: impact on prognosis? . Int J Colorectal Dis 19, 23–42 (2004). https://doi.org/10.1007/s00384-003-0499-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-003-0499-7